IMUNON’s DNA Vaccine Shows Strong Immune Response in Phase 1 Trial

IMUNON, Inc. has announced promising results from its Phase 1 clinical trial of IMNN-101, a DNA-based vaccine developed using its proprietary PlaCCine® technology. The trial, which involved 24 participants, showed that a single dose of IMNN-101 was not only well-tolerated but also induced a significant immune response. Participants experienced a two- to four-fold increase in neutralizing antibodies against the Omicron XBB.1.5 variant, with immunity continuing to strengthen over four weeks. Unlike existing mRNA vaccines, IMNN-101 offers greater stability at workable temperatures, making it a potential game-changer in vaccine technology.

Dr. Stacy Lindborg, CEO of IMUNON, emphasized the vaccine’s potential to address future health threats, citing its strong immunogenicity and durability. The trial’s success supports further development and potential partnerships for advancing the PlaCCine platform. Given its ability to provide robust protection without the need for booster doses, IMNN-101 could emerge as a next-generation vaccine capable of efficiently tackling emerging variants. Researchers are optimistic about its long-term benefits and are exploring opportunities to bring this innovation to a broader market.